Det konkluderes, at mens den øgede forekomst af tumorer i den første transplacentale karcinogenicitetsundersøgelse repræsenterer en hypotetisk risiko, bør dette afvejes mod den beviste terapeutiske fordel.
It is concluded that as the increase in incidence of tumours in the first transplacental carcinogenicity study represents a hypothetical risk, this should be balanced against the proven therapeutic benefit.